株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アレルギー性鼻炎治療薬の世界市場 2016年〜2026年の予測:抗ヒスタミン剤、鼻腔内コルチコステロイド、免疫療法・ワクチン市場における動向とパイプライン機会の分析

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets

発行 Visiongain Ltd 商品コード 310754
出版日 ページ情報 英文 240 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.54円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
アレルギー性鼻炎治療薬の世界市場 2016年〜2026年の予測:抗ヒスタミン剤、鼻腔内コルチコステロイド、免疫療法・ワクチン市場における動向とパイプライン機会の分析 Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets
出版日: 2016年09月16日 ページ情報: 英文 240 Pages
概要

世界のアレルギー性鼻炎薬市場額は2026年に165億米ドルに達する見込みで、2016-2026年の期間中は高い収益成長が見込まれています。都市化の進展、気候変動、患者の期待の増加、高いアレルギー性鼻炎発生率、新興経済国の急成長、治療薬技術の進歩などが市場の成長促進因子となっています。

当レポートでは、世界のアレルギー性鼻炎薬市場について調査し、世界市場、主要国市場および2次市場の売上予測、製品別の収益予測、R&D動向、市場の課題、市場の展望および主要企業のプロファイルなどをまとめています。

第1章 本書の概要

第2章 イントロダクション:アレルギー性鼻炎

  • 製薬産業:概要
  • アレルギーの概要
  • アレルギー性鼻炎
  • アレルギー性鼻炎の治療
  • 治験の段階
  • 調査範囲

第3章 アレルギー性鼻炎治療薬:世界市場

  • 世界のアレルギー性鼻炎治療薬市場
  • 市場の分類
  • 売上実績
  • 市場売上予測
  • セグメント別の市場シェア変化予測

第4章 経口抗ヒスタミン薬市場の分析および予測

  • 市場概要
  • 市場の動向・発展
  • 市場予測
    • 主要薬別市場シェア変化予測
  • 主要製品および製薬会社:売上実績/予測
    • アレグラ/アレグラ-D/市販用アレグラ (フェキソフェナジン) - Sanofi
    • クラリチン/市販用クラリチン (ロラタジン) - Bayer/ Merck & Co
    • ジルテック/ジルテックD(セチリジン) - Johnson & Johnson/ UCB/ GSK
    • サイザル (レボセチリジン) - Sanofi/ UCB/ GSK
    • クラリネックス (デスロラタジン) - Merck & Co.
    • アレロック (オロパタジン) - 協和発酵キリン
    • エバステル (エバスチン) - AstraZeneca/武田薬品工業/大日本住友製薬
    • タリオン (ベポタスチン) - 田辺三菱製薬
    • その他の経口抗ヒスタミン薬の売上予測

第5章 鼻腔内コルチコステロイド薬市場の分析および予測

  • 主要製品
  • 市場予測
    • 主要薬別市場シェア変化予測
  • 主要製品および製薬会社:売上予測
    • フリクソナーゼ/フロナーゼ/市販用フロナーゼ (プロピオン酸フルチカゾン) - GlaxoSmithKline
    • ナゾネックス (モメタゾン) - Merck
    • Avamys/Veramyst (フルチカゾンプロピオン酸エステル) - GlaxoSmithKline
    • リノコート (ブデソニド) - AstraZeneca
    • ナサコート/市販用ナサコート (トリアムシノロン) - Sanofi
    • オムナリス (シクレソニド) - 大日本住友製薬/武田薬品工業
    • ベコナーゼ/ベコナーゼAQ (ベクロメタゾン) - GlaxoSmithKline/Omega Pharma
    • Qnasl (ベクロメタゾン) - Teva
    • Zetonna (シクレソニド)- 大日本住友製薬

第6章 免疫療法・ワクチン市場の分析および予測

  • 市場概要
  • 主な免疫療法製品
  • 市場の動向・発展
  • 市場予測
    • 主要薬別市場シェア変化予測
  • 投薬経路別免疫療法の種類:投与経路別
  • 主要製品および製薬会社:売上予測
    • Staloral (草の花粉のアレルゲンエキス) - Stallergenes
    • Alutard SQ (草の花粉のアレルゲンエキス) - ALK-Abello
    • Grazax/Grastek (オオアワガエリ花粉のアレルゲンエキス) - ALK-Abello/Merck
    • Oralair (草の花粉のアレルゲンエキス) - Stallergenes/Greer
    • Ragwitek (ブタクサ花粉のアレルゲンエキス) - Merck
    • その他の免疫療法製品

第7章 鼻腔内抗ヒスタミン薬市場の分析および予測

  • 主要製品
  • 市場の動向・発展
  • 市場予測
    • 主要薬別市場シェア変化予測
  • 主要製品および製薬会社:売上予測
    • ダイミスタ (アゼラスチン/フルチカゾン) - Meda Pharmaceuticals
    • 鼻腔内投与用アゼラスチンのジェネリック医薬品
    • アステプロ (アゼラスチン) - Meda Pharmaceuticals
    • パタネーゼ (オロパタジン) - Novartis
    • アステリン (アゼラスチン) - Meda Pharmaceuticals

第8章 主要国のアレルギー性鼻炎治療薬市場

  • 世界のアレルギー性鼻炎治療薬市場の地域的内訳
  • 主要国市場予測
    • 国別の市場シェア変化予測
  • 地域別市場の分析および予測
  • 米国市場:最大の市場
    • 動向・発展
      • 処方薬からOTC薬へ
    • 市場予測
  • EU5ヶ国
    • 市場予測
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • 中国市場
    • 大気汚染に関連したと有病率の上昇
    • 医療保険と医療費償還の拡大
    • 市場予測
  • 日本
    • 杉林の再生と花粉症の流行
    • 免疫療法としての遺伝子組み換え米
    • ジェネリック医薬品普及率の上昇効果
    • 市場予測
  • ロシア
    • ロシアの経済状況が医薬品産業に与える影響
    • 市場予測
  • インド
    • インドの医薬品産業における薬価管理法の影響
    • 医療保険の供給拡大
    • 市場予測
  • ブラジル
    • 医療保険の成長がアレルギー性鼻炎薬に与える影響
    • 市場予測
  • その他の地域

第9章 アレルギー性鼻炎薬の主要企業

  • アレルギー性鼻炎薬:進化する市場空間
  • ALK-Abello
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • 協和発酵キリン
  • Merck & Co.
  • Sanofi
  • Stallergenes Greer
  • UCB
  • その他の主要企業

第10章 アレルギー性鼻炎薬のパイプライン分析

  • 動向・発展
  • 経口抗ヒスタミン薬パイプライン
  • 鼻腔内コルチコステロイド薬パイプライン
  • 免疫療法パイプライン
  • その他のアレルギー性鼻炎薬のパイプライン

第11章 アレルギー性鼻炎薬市場の定性分析

  • アレルギー性鼻炎薬に影響を与える市場因子
  • SWOT分析
  • ポーターのファイブフォース分析

第12章 調査インタビュー

第13章 結論

  • 最新市場状況および市場予測
  • アレルギー性鼻炎薬市場の主要部門
  • アレルギー性鼻炎薬市場の主要地域
  • アレルギー性鼻炎薬の主要企業
  • アレルギー性鼻炎薬市場の将来

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0142

Title:
ALLERGIC RHINITIS DRUGS MARKET FORECAST 2016-2026
Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co..

What can be expected from the Allergic Rhinitis Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 240-page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the allergic rhinitis drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2026? Our study forecasts revenues in the following Allergic Rhinitis Drugs submarkets:

  • Intranasal Anthistamines
  • Intranasal Corticosteroids
  • Oral Antihistamines
  • Immunotherapy and Vaccines

See detailed profiles or revenue forecasts for some the leading products in the market

How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the allergic rhinitis drugs market including:

  • Patanase
  • Astepro
  • Astelin
  • Dymista
  • Nasonex
  • Avamys
  • Veramyst
  • Flixonase
  • Rhinocort
  • Omnaris
  • Nasacort
  • Beconase
  • Qnasl
  • Zetonna
  • Allegra
  • Zyrtec
  • Claritin
  • Xyzal
  • Allelock
  • Clarinex
  • Ebastel
  • Talion
  • Staloral
  • Alutard SQ
  • Grazax
  • Ragwitek

See revenue forecasts for the leading international markets

How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:

  • US
  • EU5 - Germany, UK, France, Italy and Spain
  • China
  • Japan
  • India
  • Russia
  • Brazil

Leading companies and potential for market growth

Visiongain forecasts overall revenue for the Allergic Rhinitis Drugs Market will reach $16,500m in 2026. We predict a high revenue growth over the forecast period driven by an urbanisation, climate change, increasing patient expectations and a higher incidence of allergic rhinitis symptoms, rapid growth of emerging economies and emerging allergic rhinitis drug technologies.

Our work analyses the key companies in the market. See visiongain's analysis of six leading companies, including these:

  • GSK
  • Merck & Co
  • Sanofi
  • Johnson & Johnson
  • ALK-Abello
  • UCB
  • Kyowo Hako Kirin
  • Stallergenes Greer

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the allergic rhinitis drugs industry?

Our new report discusses issues and events affecting the allergic rhinitis drugs market. You will find discussions, including qualitative analyses:

  • Highly competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future paradigm-shifting pipeline products
  • Patent expirations and invalidations of major drugs
  • Launches of new drug categories

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co.

In summary, our 240-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Allergic Rhinitis Drugs market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading allergic rhinitis drugs in the following areas: intranasal corticosteroids, intranasal antihistamines, oral antihistamines, and immunotherapy and vaccines.
  • Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the allergic rhinitis drugs market - discover prospects for leading allergic rhinitis drugs: Patanase, Astepro, Astelin, Dymista, Nasonex, Avamys, Veramyst, Fixonase, Rhinocort, Omnaris, Nasacort, Beconase, Qnasl, Zetonna, Allegra, Zyrtec, Claritin, Xyzal, Allelock, Clarinex, Ebastel, Talion, Staloral, Alutard SQ, Grazax, Ragwitek.
  • Revenue forecasts to 2026 for eleven leading national markets and one leading regional markets - US, EU5, China, Japan, India, Russia, and Brazil.
  • Assessment of eight leading companies - analysis of products, revenue, mergers & acquisitions, product type and product pipelines
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the over the counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Allergic Rhinitis Drugs: Market Overview
  • 1.2. Global Allergic Rhinitis Drugs Market Segmentation
  • 1.3. Overview of Findings
  • 1.4. Structure of the Report
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
  • 1.10. Frequently Asked Questions(FAQ)
  • 1.11. Associated Visiongain Reports
  • 1.12. About Visiongain

2. An Introduction to Allergic Rhinitis Drugs

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1. Allergic Rhinitis Treatments - An Industry Overview
  • 2.2. A Brief Overview of Allergy
  • 2.3. Allergic Rhinitis
    • 2.3.1. The Global Prevalence of Allergic Rhinitis
    • 2.3.2. Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
    • 2.3.3. Symptoms of Allergic Rhinitis
    • 2.3.4. Classification of Allergic Rhinitis
      • 2.3.4.1. Non-Allergic Rhinitis and Mixed Rhinitis
    • 2.3.5. Seasonal Allergic Rhinitis(Hay Fever)
    • 2.3.6. Perennial Allergic Rhinitis
    • 2.3.7. Diagnosis of Allergic Rhinitis
  • 2.4. Treatment of Allergic Rhinitis
    • 2.4.1. Antihistamines
      • 2.4.1.1. First-Generation Antihistamines
      • 2.4.1.2. Second- And Third-Generation Antihistamines
    • 2.4.2. Corticosteroids
      • 2.4.2.1. First-, Second- And Third-Generation Intranasal Corticosteroids
      • 2.4.2.2. Combination Drug Products
    • 2.4.3. Leukotriene Receptor Antagonists
    • 2.4.4. Cromolyn(cromoglicic acid)
    • 2.4.5. Decongestants
    • 2.4.6. Saline Nasal Sprays
    • 2.4.7. Immunotherapy and Vaccines
  • 2.5. Phases of Clinical Trials
  • 2.6. Scope of this Report

3. The Global Allergic Rhinitis Drugs Market, 2016-2026

  • 3.1. The Global Allergic Rhinitis Drugs Market: Market Overview
  • 3.2. Categorisation Of The Global Allergic Rhinitis Drugs Market
  • 3.3. The Global Allergic Rhinitis Drugs Market in 2015
  • 3.4. The Global Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 3.5. Allergic Rhinitis Drugs: Changing Market Shares by Sector 2016-2026

4. Oral Antihistamines Market: Market Analysis And Forecast 2016-2026

  • 4.1. Oral Antihistamines: Market Overview
    • 4.1.1. Leading Products in the Oral Antihistamines Market, 2015
  • 4.2. Oral Antihistamines: Market Trends and Developments, 2016
    • 4.2.1. Patent Expiries and the Threat of Generics
    • 4.2.2. The Increasing Switch from Prescription to Over-The-Counter Sales
    • 4.2.3. The Potential for Combination Therapy with Intranasal Corticosteroids
  • 4.3. Oral Antihistamines: Market Forecast 2016-2026
    • 4.3.1. Oral Antihistamines: Changing Market Shares by Leading Drugs 2016-2026
  • 4.4. Leading Oral Antihistamines for the Treatment of Allergic Rhinitis
    • 4.4.1. Allegra/Allegra-D/Allegra OTC(fexofenadine)-Sanofi
      • 4.4.1.1. Allegra/Allegra OTC: Historical Sales, 1995-2014
      • 4.4.1.2. Allegra/Allegra OTC: Sales Forecast 2015-2026
    • 4.4.2. Claritin/Claritin OTC(loratadine) - Bayer/ Merck & Co
      • 4.4.2.1. Claritin/Claritin OTC: Sales Forecast 2016-2026
    • 4.4.3. Zyrtec/Zyrtec D(cetirizine)-Johnson & Johnson/ UCB/ GSK
      • 4.4.3.1. Zyrtec/Zyrtec D: Sales Forecast 2016-2026
    • 4.4.5. Xyzal(levocetirizine)-Sanofi/ UCB/ GSK
      • 4.4.5.1. Xyzal: Sales Forecast 2016-2026
    • 4.4.6. Clarinex(desloratadine)-Merck & Co.
      • 4.4.6.1. Clarinex: Sales Forecast 2016-2026
    • 4.4.7. Allelock(olopatadine)-Kyowa Hakko Kirin
      • 4.4.7.1. Allelock: Sales Forecast 2016-2026
    • 4.4.8. Ebastel(ebastine)-AstraZeneca/Takeda/Dainippon Sumitomo
      • 4.4.8.1. Ebastel: Sales Forecast 2016-2026
    • 4.4.9. Talion(bepotastine)-Mitsubishi Tanabe
      • 4.4.9.1. Talion: Sales Forecast 2016-2026
    • 4.4.10. Other Oral Antihistamines: Sales Forecast 2016-2026

5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2016-2026

  • 5.1. Leading Products in the Intranasal Corticosteroids Market, 2015
  • 5.2. Intranasal Corticosteroids: Market Forecast 2016-2026
    • 5.2.1. Intranasal Corticosteroids: Changing Market Shares By Leading Drugs 2016-2026
  • 5.3. Leading Intranasal Corticosteroids
    • 5.3.1. Flixonase/Flonase/Flonase-OTC(fluticasone propionate)-GlaxoSmithKline
      • 5.3.1.1. Flixonase/Flonase/Flonase-OTC Forecast, 2016-2026
    • 5.3.2. Nasonex(mometasone)-Merck
      • 5.3.2.1. Nasonex Forecast, 2016-2026
    • 5.3.3. Avamys/Veramyst(fluticasone furoate)-GlaxoSmithKline
      • 5.3.3.1. Avamys/Veramyst Forecast, 2016-2026
    • 5.3.4. Rhinocort(budesonide)-AstraZeneca
      • 5.3.4.1. Rhinocort Forecast, 2016-2026
    • 5.3.5. Nasacort/Nasacort-OTC(triamcinolone)-Sanofi
      • 5.3.5.1. Nasacort/Nasacort-OTC Forecast, 2016-2026
    • 5.3.6. Omnaris(ciclesonide)-Dainippon Sumitomo/Takeda
      • 5.3.6.1. Omnaris: Sales Forecast, 2016-2026
    • 5.3.7. Beconase/Beconase AQ(beclometasone)-GlaxoSmithKline/Omega Pharma
      • 5.3.7.1. Beconase/Beconase AQ Forecast, 2016-2026
    • 5.3.8. Qnasl(beclometasone)-Teva
      • 5.3.8.1. Qnas Forecast, 2016-2026
    • 5.3.9. Zetonna(ciclesonide)-Dainippon Sumitomo
      • 5.3.9.1. Zetonna Forecast, 2016-2026

6. Immunotherapy and Vaccines: Market Analysis and Forecast 2016-2026

  • 6.1. Immunotherapy and Vaccines: Market Overview
    • 6.1.1. Immunotherapy: Primed for Rapid Expansion
  • 6.2. Leading Immunotherapy Products in the Allergic Rhinitis Market, 2015
  • 6.3. Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2016
    • 6.3.1. Subcutaneous and Sublingual Immunotherapy
    • 6.3.2. Expansion into the US Market
    • 6.3.3. Standardisation of Immunotherapy Products
    • 6.3.4. Immunotherapy as a Preventative Treatment
  • 6.4. Allergic Rhinitis Immunotherapy: Market Forecast 2016-2026
    • 6.4.1. Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2016-2026
  • 6.5. Immunotherapy Type - By Route of Administration, 2015
  • 6.6. Leading Immunotherapy Products for Allergic Rhinitis
    • 6.6.1. Staloral(Grass pollen allergen extract)-Stallergenes
      • 6.6.1.1. Staloral: Sales Forecast 2016-2026
    • 6.6.2. Alutard SQ(Grass pollen allergen extract)-ALK-Abelló
      • 6.6.2.1. Alutard SQ: Sales Forecast 2016-2026
    • 6.6.3. Grazax/Grastek(Timothy grass pollen allergen extract)-ALK-Abelló/Merck
      • 6.6.3.1. Grazax/Grastek: Sales Forecast 2016-2026
    • 6.6.4. Oralair(Grass pollen allergen extract)-Stallergenes/Greer
      • 6.6.4.1. Oralair: Sales Forecast 2016-2026
    • 6.6.5. Ragwitek(Short ragweed pollen allergen extract)-Merck
      • 6.6.5.1. Ragwitek: Sales Forecast 2016-2026
    • 6.6.6. Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2016-2026

7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2016-2026

  • 7.1. Leading Products in the Intranasal Antihistamines Market, 2015
  • 7.2. Intranasal Antihistamines: Market Trends and Developments, 2016
  • 7.3. Intranasal Antihistamines: Market Forecast 2016-2026
  • 7.4. Leading Intranasal Antihistamines
    • 7.4.1. Dymista(azelastine/fluticasone)-Meda Pharmaceuticals
      • 7.4.1.1. Mylan Acquires Meda Pharmaceuticals
      • 7.4.1.2. Dymista: Sales Forecast 2016-2026
    • 7.4.2. Generic Intranasal Azelastine
      • 7.4.2.1. Generic Intranasal Azelastine: Sales Forecast, 2016-2026
    • 7.4.3. Astepro(azelastine) - Meda Pharmaceuticals
      • 7.4.3.1. Astepro: Sales Forecast 2016-2026
    • 7.4.4. Patanase(olopatadine)-Novartis
      • 7.4.4.1. Patanase: Sales Forecast 2016-2026
    • 7.4.5. Astelin(azelastine)-Meda Pharmaceuticals
      • 7.4.5.1. Astelin: Sales Forecast 2016-2026

8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2026

  • 8.1. The Allergic Rhinitis Drugs Market by Region
    • 8.1.1. The Global Distribution of Allergic Rhinitis Drugs in 2015
  • 8.2. Leading National Markets: Forecast 2016-2026
    • 8.2.1. Changing Market Shares by Region, 2016-2026
  • 8.3. Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2016-2026
    • 8.3.1. United States: The Largest Allergic Rhinitis Drugs Market
      • 8.3.1.1. US Allergic Rhinitis Drugs Market: Trends and Developments
        • 8.3.1.1.1. The Trend of Rx-to-OTC Switching
      • 8.3.1.2. US Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
    • 8.3.2. EU5
      • 8.3.2.1. EU5. Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
      • 8.3.2.2. EU5. Markets: Changing Market Shares by Country, 2016-2026
      • 8.3.2.3. Germany
        • 8.3.2.3.1. Germany: Reform of AMNOG Pharmaceutical Rebate Law
        • 8.3.2.3.2. German Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
      • 8.3.2.4. UK
        • 8.3.2.4.1. UK: Increasing Burden of Allergy
        • 8.3.2.4.2. UK Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
      • 8.3.2.5. France
        • 8.3.2.5.1. France: Social Security Finance Act 2015
        • 8.3.2.5.2. French Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
      • 8.3.2.6. Italy
        • 8.3.2.6.1. Italy: Government Cost Cutting Measures Impacting Market Growth
        • 8.3.2.6.2. Italian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
      • 8.3.2.7. Spain
        • 8.3.2.7.1. Spanish Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 8.6. China
    • 8.6.1. Air Pollution Associated With Increasing Prevalence
    • 8.6.2. Expansion of Healthcare Coverage and Reimbursement in China
    • 8.6.3. Chinese Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 8.7. Japan
    • 8.7.1. Cedar Reforestation and the Hay Fever Epidemic
    • 8.7.2. Genetically Modified Rice as Immunotherapy
    • 8.7.3. Effects of the Rising Levels of Generic Drug Penetration
    • 8.7.4. Japanese Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 8.8. Russia
    • 8.8.1. How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.8.2. Russian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 8.9. India
    • 8.9.1. The Impact of the Drug Prices Control Order on Indian Pharma
    • 8.9.2. India's Expansion of Healthcare Provision
    • 8.9.3. Indian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 8.10. Brazil
    • 8.10.1. How Will Brazil's Growing Healthcare Influence Allergic Rhinitis Drugs
    • 8.10.2. Brazilian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
  • 8.12. Rest of the World
    • 8.12.1. Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2016-2026

9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2026

  • 9.1. Allergic Rhinitis Drugs - An Evolving Market Space
    • 9.1.1. Leading Companies in the Allergic Rhinitis Drugs Market, 2016
  • 9.2. ALK-Abelló
    • 9.2.1. ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2016
    • 9.2.2. ALK-Abelló: Recent Developments
      • 9.2.2.1. Acarizax Launched in Europe progressing to International Roll-Out
      • 9.2.2.2. ALK Collaborates With EddingPharm to Boost China Sales
      • 9.2.2.3. ALK-Abelló: Sales Forecast 2016-2026
      • 9.2.2.4. ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2016
  • 9.3. GlaxoSmithKline(GSK)
    • 9.3.1. GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2016
    • 9.3.2. GlaxoSmithKline: Sales Forecast 2016-2026
  • 9.4. Johnson & Johnson
    • 9.4.1. Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2016
    • 9.4.2. Johnson & Johnson: Recent Developments
      • 9.4.2.1. Manufacturing Recalls At McNeil Consumer Healthcare
      • 9.4.2.2. Johnson & Johnson: Sales Forecast 2016-2026
  • 9.5. Kyowa Hakko Kirin
    • 9.5.1. Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.5.2. Kyowa Hakko Kirin: Sales Forecast 2016-2026
  • 9.6. Merck & Co.
    • 9.6.1. Merck: Allergic Rhinitis Drugs Portfolio, 2016
    • 9.6.2. Merck: Recent Developments
      • 9.6.2.1. Bayer Acquires Merck's Consumer Health Business
      • 9.6.2.2. FDA Rejects Singulair OTC Switch
      • 9.2.6.3. Merck: Sales Forecast 2016-2026
      • 9.2.6.4. Merck: Allergic Rhinitis Drug Development Pipeline, 2016
  • 9.7. Sanofi
    • 9.7.1. Sanofi: Allergic Rhinitis Drugs Portfolio, 2016
    • 9.7.2. Sanofi: Sales Forecast 2016-2026
  • 9.8. Stallergenes Greer
    • 9.8.1. Stallergenes: Allergic Rhinitis Drugs portfolio, 2015
    • 9.8.2. Stallergenes Greer: Sales Forecast 2016-2026
    • 9.8.3. Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2015
  • 9.9. UCB
    • 9.9.1. UCB: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.9.2. UCB: Sales Forecast 2016-2026
  • 9.10. Other Leading Companies within the Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2026

  • 10.1. Trends and Developments in the Allergic Rhinitis Pipeline
  • 10.2. The R&D Pipeline for Oral Antihistamines, 2016
    • 10.2.1. Talion(bepotastine)-Mitsubishi Tanabe
    • 10.2.2. ZPL-3893787(histamine H4R antagonist)-Ziarco Pharma
  • 10.3. The R&D Pipeline for Intranasal Corticosteroids, 2016
    • 10.3.1. APC-3000(HFA inhaled corticosteroid)-Adamis Pharmaceuticals
    • 10.3.2. TBS-6-Trimel Pharmaceuticals
  • 10.4. The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2016
    • 10.4.1. Actair(house dust mite SLIT; STG320)-Stallergenes/Shionogi & Co
    • 10.4.2. AllerT(subcutaneous birch pollen immunotherapy)-Anergis
    • 10.4.3. Depigoid Birch 5000(birch pollen allergen extract, Leti Pharma
    • 10.4.4. House Dust Mite SLIT-Tablet(MK-8237)-ALK-Abelló/Merck/Torii
    • 10.4.5. Pollinex Quattro(subcutaneous immunotherapies)-Allergy Therapeutics
    • 10.4.6. gp-ASIT+(grass pollen allergen fragments)-Biotech Tools
    • 10.4.7. Betula verrucosa(Bet v) 1 allergen - Stallergenes Greer
  • 10.5. The R&D Pipeline for Other Allergic Rhinitis Drugs
    • 10.5.1. S-555739(prostaglandin D2 receptor antagonist)-Shionogi
    • 10.5.2. DSP-3025/AZD-8848(toll-like receptor 7 agonist)-Dainippon Sumitomo/ AstraZeneca
    • 10.5.3. GSK2245035(toll-like receptor 7 agonist)-GSK
    • 10.5.4. HP-3060(transdermal long-acting tape)-Hisamitsu
    • 10.5.5. MRX-4(anti-inflammatory agent)-Celsus Therapeutics

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2026

  • 11.1. Market Factors Influencing Allergic Rhinitis Drugs
  • 11.2. SWOT Analysis Of The Global Allergic Rhinitis Drugs Market, 2016-2026
    • 11.2.1. Strengths
      • 11.2.1.1. OTC-Switch Facilitating Ease Of Consumer Access
      • 11.2.1.2. The Established Role Of Allergic Rhinitis Drugs In Treatment
      • 11.2.1.3. Allergic Rhinitis And The Rising Unmet Clinical Need
      • 11.2.1.4. Rising Profile of Allergic Rhinitis In Various Regions Driving Healthcare Provision
    • 11.2.2. Weaknesses
      • 11.2.2.1. Intranasal Corticosteroids And Patients' Satisfaction Rates
      • 11.2.2.2. Increasing Penetration Of Generic Drug Products
      • 11.2.2.3. The Challenge Raised By The Low Volume Of Pipeline Developments
    • 11.2.3. Opportunities
      • 11.2.3.1. Growth In Emerging Markets Outstripping Established Markets
      • 11.2.3.2. Rx-to-OTC Switching And The Effects On Revenue Potential
      • 11.2.3.3. Combination Drug Products Providing Rising Efficacy Profiles
      • 11.2.3.4. The Emergence Of Immunotherapy In Allergic Rhinitis
    • 11.2.4. Threats
      • 11.2.4.1. Cost-Containment As A Growth Restraint
      • 11.2.4.2. Rising Cost Of APIs And Manufacturing
      • 11.2.4.3. Patent Expiries And The Resultant Loss Of Revenue
  • 11.3. Porter's Five Force Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2026
    • 11.3.1. Power of Buyers
    • 11.3.2. Power Of Suppliers
    • 11.3.3. Threat of Substitutes
    • 11.3.4. Threat Of New Entrants
    • 11.3.5. Rivalry Among Competitors

12. Conclusions

  • 12.1. Overview of Current Market Conditions and Market Forecast, 2015-2026
  • 12.2. Leading Sectors in the Allergic Rhinitis Drugs Market in 2015
  • 12.3. Leading Regions in the Allergic Rhinitis Drugs Market in 2015
  • 12.4. Leading Companies in the Allergic Rhinitis Drugs Market, 2015
  • 12.5. What Does The Future Hold For Allergic Rhinitis Drugs?
  • Associated Reports
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 1.1: Allergic Rhinitis Market Forecast by National Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 2.1: Leading Antihistamines for Allergic Rhinitis, 2015
  • Table 2.2: Leading Corticosteroids for Allergic Rhinitis, 2016
  • Table 2.3: Clinical Trial Phases
  • Table 3.1: The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2015
  • Table 3.2: The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 3.4: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2015, 2020, 2026
  • Table 4.1: Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2015
  • Table 4.2: Oral Antihistamines Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.3: The Global Oral Antihistamines Market: Market Share (%), 2015, 2020, 2026
  • Table 4.4: Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.5: Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.6: Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.7: Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.8: Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.9: Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.10: Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.11: Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.12: Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.1: Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2015
  • Table 5.2: Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 5.3: The Global Intranasal Corticosteroids Market: Market Share (%), 2015, 2020, 2026
  • Table 5.4: Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
  • Table 5.5: Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.6: Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.7: Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.8: Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.9: Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.10: Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.11: Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.12: Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.1: Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2015
  • Table 6.2: Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.3: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2015, 2020, 2026
  • Table 6.4: Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2015
  • Table 6.5: Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.6: Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.7: Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.8: Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.9: Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.10: Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.1: Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2015
  • Table 7.2: Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2015-2026
  • Table 7.3: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2015, 2020, 2026
  • Table 7.4: Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.5: Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.6: Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2015-2025
  • Table 7.7: Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.8: Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.1: The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2015
  • Table 8.2: Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.3: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2015, 2020, and 2026
  • Table 8.4: US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.5: The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2015
  • Table 8.6: The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.7: The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2015, 2020, 2026
  • Table 8.8: German Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.9: UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.10: French Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
  • Table 8.11: Italian Allergic Rhinitis Drugs Market Forecat: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
  • Table 8.12: Spanish Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
  • Table 8.13: Chinese Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.14: Japanese Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2015-2026
  • Table 8.15: Russian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.16: Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.17: Brazilian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.18: Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2015-2026
  • Table 9.1: Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2015
  • Table 9.2: ALK- Abelló: Company Overview, 2016
  • Table 9.3: ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 9.4: GlaxoSmithKline: Company Overview, 2016
  • Table 9.5: GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 9.6: Johnson & Johnson: Company Overview, 2016
  • Table 9.7: Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 9.8: Kyowa Hakko Kirin: Company Overview, 2016
  • Table 9.9: Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 9.10: Merck & Co: Company Overview, 2016
  • Table 9.11: Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.12: Sanofi: Company Overview, 2016
  • Table 9.13: Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.14: Stallergenes Greer: Company Overview, 2015
  • Table 9.15: Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.16: UCB: Company Overview, 2016
  • Table 9.17: UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 11.1: SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2026

List of Figures

  • Figure 1.1: Global Allergic Rhinitis Drugs Market: Market Sectors, 2015
  • Figure 2.1: Role of Mast Cells and IgE in Allergic Rhinitis, 2016
  • Figure 3.1: The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2015
  • Figure 3.2: The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2015-2026
  • Figure 3.3: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2015
  • Figure 3.4: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2020
  • Figure 3.5: The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2026
  • Figure 4.1: Leading Oral Antihistamines: Revenue ($m), 2015
  • Figure 4.2: Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.3: The Global Oral Antihistamines Market: Market Share(%), 2015
  • Figure 4.4: The Global Oral Antihistamines Market: Market Share (%), 2020
  • Figure 4.5: The Global Oral Antihistamines Market: Market Share (%), 2026
  • Figure 4.6: Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2015
  • Figure 4.7: Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.8: Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.9: Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.10: Xyzal Forecast: Revenue($m) and AGR (%), 2015-2026
  • Figure 4.11: Clarinex Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.12: Allelock Forecast: Revenue($m) and AGR (%), 2015-2026
  • Figure 4.13: Ebastel Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.14: Talion Forecast: Revenue($m) and AGR (%), 2015-2026
  • Figure 4.15: Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.1: Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2014
  • Figure 5.2: Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.3: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2015
  • Figure 5.4: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2020
  • Figure 5.5: The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2026
  • Figure 5.6: Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.7: Nasonex Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.8: Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.9: Rhinocort Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.10: Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.11: Omnaris Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.12: Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.13: Qnasl Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.14: Zetonna Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.1: Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2015
  • Figure 6.2: Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.3: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2015
  • Figure 6.4: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2020
  • Figure 6.5: The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2026
  • Figure 6.6: Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2015
  • Figure 6.7: Staloral Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.8: Alutard SQ Forecast: Revenue($m) and AGR (%), 2015-2026
  • Figure 6.9: Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2015-2026
  • Figure 6.10: Oralair Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.11: Ragwitek Forecast: Revenue ($m) and AGR (%), 201-2026
  • Figure 6.12: Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 7.1: Top Drugs In The Intranasal Antihistamines Market: Revenue ($m), 2015
  • Figure 7.2: Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 7.3: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2015
  • Figure 7.4: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2020
  • Figure 7.5: The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%, 2026
  • Figure 7.6: Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR(%), 2015-2026
  • Figure 7.7: Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2015-2026
  • Figure 7.8: Astepro Forecast: Revenue ($m), and AGR (%), 2015-2026
  • Figure 7.9: Patanase Forecast: Revenue($m) and AGR (%), 2015-2026
  • Figure 7.10: Astelin Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 8.1: The Global Allergic Rhinitis Drugs Market By Region: Revenue ($m), 2015
  • Figure 8.2: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2015
  • Figure 8.3: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2020
  • Figure 8.4: The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2026
  • Figure 8.5: US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.6: The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2015
  • Figure 8.7: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2015
  • Figure 8.8: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2020
  • Figure 8.9: The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2026
  • Figure 8.10: German Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.11: UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.12: French Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.13: Italian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.14: Spanish Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.15: Chinese Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.16: Japanese Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.17: Russian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.18: Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.19: Brazilian Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.20: Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 9.1: Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m), 2015
  • Figure 9.2: ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 9.3: GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 9.4: Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 9.5: Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 9.6: Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 9.7: Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.8: Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.9: UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 11.1: Porter's Five Force Analysis of the Allergic Rhinitis Drugs Market, 2016

Companies Listed

  • ActoGeniX
  • Adamis Pharmaceuticals
  • ALK- Abelló
  • Allergy Medical UK
  • Allergy Therapeutics
  • Almirall
  • Altana Pharma (Nycomed)
  • Anergis
  • Apotex
  • AstraZeneca
  • Atopix Therapeutics
  • Barr Laboratories
  • Bausch & Lomb
  • Belcher Pharmaceuticals
  • Biotech Tools
  • Catalent Pharma Solutions
  • Celsus Therapeutics
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy's Laboratories
  • Eddingpharm
  • Eleventa
  • Genzyme (Sanofi)
  • GlaxoSmithKline
  • Greer Laboratories
  • Hisamitsu Pharmaceutical Co
  • Hoechst AG
  • Human Genome Sciences
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Keldman Healthcare
  • Kyowa Hakko Kirin
  • Leti Pharma (Laboratorios Leti)
  • Lupin Pharmaceuticals
  • Meda Pharma
  • Medpointe Inc (Meda Pharma)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nippon Paper Group
  • Novartis
  • Omega Pharma
  • Perrigo
  • Pfizer
  • ProStrakan (Kyowa Hakko Kirin)
  • Reckitt Benckiser
  • Roxane Laboratories (Boehringer Ingelheim)
  • Sanofi
  • Schering-Plough (Merck)
  • Shionogi & Co Ltd
  • Stallergenes
  • Sun Pharmaceuticals
  • Sunovion Pharmaceuticals (Dainippon Sumitomo)
  • Takeda
  • Teva Pharmaceuticals
  • Trimel Pharmaceuticals
  • Ube Industries
  • UCB
  • ViiV Healthcare
  • Wockhardt
  • Ziarco Pharma

Organisations Mentioned in this Report

  • Allergy & Asthma Network
  • AllergyUK
  • American Academy of Allergy, Asthma and Immunology (AAAAI)
  • British Society for Allergy & Clinical Immunology (BSACI) [UK]
  • Farmácia Popular [Brazil]
  • Imperial College London
  • International Nurses Group In Immunodeficiencies
  • Japanese Ministry of Health, Labour and Welfare
  • Les Entreprises Du Médicament (Leem) [France]
  • National Development and Reform Commission (NDRC) [China]
  • National Pharmaceutical Pricing Authority (NPPA) [India]
  • PollenUK
  • The Pharmaceutical Research and Manufacturers of America (PhRMA)
  • The UK Health and Social Care Information Centre
  • Université Libre de Bruxelles [Belgium]
  • University of Leuven [Belgium]
  • US Attorney's Office for the Eastern District of Pennsylvania
  • US Food and Drug Administration (FDA)
  • World Allergy Organisation
  • World Health Organisation (WHO)
Back to Top